Although newly generated PKC inhibitors have shown promise in the treatment of macular edema [54], retinopathy [55], and microvascular complications [56] in diabetic patients, targeting upstream activators could be a therapeutic strategy for the development of inhibitors able to prevent or delay vascular complications in the early stages of diabetes mellitus. Here, PRRT2 is linked to retinal disorder.